146 related articles for article (PubMed ID: 903996)
1. Immune responses to mouse neuroblastoma C1300. I. Preliminary observations on cell-mediated immune responses.
Phillips ME; Cipuzak PM; Penta DD; Schachner M
J Natl Cancer Inst; 1977 Oct; 59(4):1215-9. PubMed ID: 903996
[TBL] [Abstract][Full Text] [Related]
2. Immune responses to mouse neuroblastoma C1300. II. Cell-mediated kinetics and specificity studies.
Della Penta D; Cipuzak PM; Phillips ME
Int Arch Allergy Appl Immunol; 1982; 69(4):322-9. PubMed ID: 7141715
[TBL] [Abstract][Full Text] [Related]
3. Ultrastructural studies of C1300 neuroblastoma cell interaction with syngeneic spleen lymphoid cells.
Procicchiani G; Fiorani M; Revoltella R
Cell Immunol; 1979 Apr; 44(1):39-50. PubMed ID: 455475
[No Abstract] [Full Text] [Related]
4. Protection of mice against syngeneic C1300 neuroblastoma challenge by immunization with membranes of C1300 neuroblastoma cells.
Lauro G; Businaro R; Butler RH; Revoltella R
J Natl Cancer Inst; 1980 May; 64(5):1169-72. PubMed ID: 6929017
[TBL] [Abstract][Full Text] [Related]
5. In vitro stimulation of mouse lymphoid cells by C1300 neuroblastoma cells or tumor membrane extracts.
Revoltella R; Bertolini L; Diamond L
Int J Cancer; 1976 Oct; 18(4):521-9. PubMed ID: 61946
[TBL] [Abstract][Full Text] [Related]
6. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic acid allogeneic tumors. I. Distribution of reactivity and specificity.
Herberman RB; Nunn ME; Lavrin DH
Int J Cancer; 1975 Aug; 16(2):216-29. PubMed ID: 50294
[TBL] [Abstract][Full Text] [Related]
7. Development of tumor cell resistance to syngeneic cell-mediated cytotoxicity during growth of ascitic mastocytoma P815Y.
Biddison WE; Palmer JC
Proc Natl Acad Sci U S A; 1977 Jan; 74(1):329-33. PubMed ID: 402006
[TBL] [Abstract][Full Text] [Related]
8. Adoptive transfer of cytotoxic T lymphocytes induced by CD86-transfected tumor cells suppresses multi-organ metastases of C1300 neuroblastoma in mice.
Enomoto A; Kato K; Yagita H; Okumura K
Cancer Immunol Immunother; 1997 Jun; 44(4):204-10. PubMed ID: 9222278
[TBL] [Abstract][Full Text] [Related]
9. Blastogenic response of spleen cells from C1300 neuroblastoma-bearing mice to tumor cells or soluble and insoluble tumor antigens.
Sugimoto T; Sawada T; Tozawa M; Kusunoki T; Kishida T
Gan; 1979 Jun; 70(3):327-36. PubMed ID: 157310
[TBL] [Abstract][Full Text] [Related]
10. Cellular and humoral immunity to leukemia cells in BCG-induced growth control of a murine leukemia.
Olsson L; Florentin I; Kiger N; Mathé G
J Natl Cancer Inst; 1977 Oct; 59(4):1297-306. PubMed ID: 904001
[TBL] [Abstract][Full Text] [Related]
11. Tumor immunization. Improved results after vaccine modified with recombinant interferon gamma.
Sigal RK; Lieberman MD; Reynolds JV; Williams N; Ziegler MM; Daly JM
Arch Surg; 1990 Mar; 125(3):308-12. PubMed ID: 2106310
[TBL] [Abstract][Full Text] [Related]
12. Mediation of immune responses to tumor antigens in vitro by immune RNA.
Kern DH; Drogemuller CR; Pilch YH
Ann N Y Acad Sci; 1976; 276():278-302. PubMed ID: 1071964
[TBL] [Abstract][Full Text] [Related]
13. A comparison of in vitro cell-mediated reactivity against syngeneic tumor cells by various lymphoid cell populations from Bacillus Calmette-Guérin-tumor-cured, tumor-sensitized, tumor-bearing, and normal inbred guinea pigs.
Fidler IJ; Kataoka T; Hanna MG
Cancer Res; 1976 Dec; 36(12):4459-66. PubMed ID: 187324
[TBL] [Abstract][Full Text] [Related]
14. A microcytotoxicity assay using 51Cr for measuring specific cell-mediated and humoral immune responses.
Della Penta D; Cipuzak PM; Phillips ME
Int Arch Allergy Appl Immunol; 1979; 60(3):332-45. PubMed ID: 489137
[TBL] [Abstract][Full Text] [Related]
15. Impaired tumorigenicity of IL-4-producing murine neuroblastoma cells in immunodeficient nude mice.
Yoshida H; Enomoto H; Miyauchi M; Takenaga K; Tanabe M; Ohnuma N; Sakiyama S; Tagawa M
Int J Oncol; 1998 May; 12(5):1067-71. PubMed ID: 9538130
[TBL] [Abstract][Full Text] [Related]
16. Rapidly acquired cytotoxicity of lymphoid cells from ice inoculated with allogeneic spleen cells.
Slavina EG; Karmanova NV; Leipunskaya IL; Zinzar SN; Reinhöfer J; Svet-Moldavsky GJ
J Natl Cancer Inst; 1976 Dec; 57(6):1233-6. PubMed ID: 1003557
[TBL] [Abstract][Full Text] [Related]
17. Alloreactivity and tumor antigens: generation of syngeneic antilymphoma killer lymphocytes by alloimmunization of mice with normal cells.
Sensi ML; Parenza M; Parmiani G
J Natl Cancer Inst; 1983 Feb; 70(2):291-7. PubMed ID: 6571938
[TBL] [Abstract][Full Text] [Related]
18. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
Lynch DH; Daynes RA; Hodes RJ
J Immunol; 1986 Feb; 136(4):1521-7. PubMed ID: 2418117
[TBL] [Abstract][Full Text] [Related]
19. Studies of the mechanisms for the induction of in vivo tumor immunity. II. Distribution and homing of cytotoxic effector and precursor cells.
Ting CC
J Natl Cancer Inst; 1978 Feb; 60(2):437-44. PubMed ID: 304488
[TBL] [Abstract][Full Text] [Related]
20. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
Gordon WC; Prager MD
Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
